Key result
Presenting hs-cTnT concentrations below 5 ng/L were 94.4% sensitive (95% CI 88.8-97.7) for 30-day MACE, identifying patients at very low risk when presenting >3 hours after symptom onset.
Why the study?
Very low hs-cTnT thresholds on presentation rule out AMI, but their ability to identify patients at low risk of 30-day MACE is less clear.
Does a presenting hs-cTnT concentration < 5 ng/L rule out 30-day MACE in patients presenting to the emergency department with chest pain and nonischemic ECGs?
Cohort (n=1,167)
Does a presenting hs-cTnT concentration < 5 ng/L rule out 30-day MACE in patients presenting to the emergency department with chest pain and nonischemic ECGs?
Effect estimate: Sensitivity 94.4% (95% CI 88.8-97.7)
A single hs-cTnT measurement below the limit of detection (<5 ng/L) in patients with chest pain for >3 hours and nonischemic ECGs effectively rules out 30-day MACE, potentially avoiding further unnecessary testing.
Very low hs-cTnT may identify low-risk ED chest pain patients; leaves open whether further testing can be safely omitted without prospective validation.
BACKGROUND: Very low high-sensitivity cardiac troponin T (hs-cTnT) thresholds on presentation can rule out acute myocardial infarction (AMI), but the ability to identify patients at low risk of 30-day major adverse cardiac events (MACE) is less clear. This study examines the sensitivity of low concentrations of hs-cTnT on presentation to rule out 30-day MACE. METHODS: This prospective cohort study enrolled patients with chest pain presenting to the emergency department with nonischemic electrocardiograms who underwent AMI rule-out with an hs-cTnT assay. The primary outcome was 30-day MACE; secondary outcomes were individual MACE components. Because guidelines recommend using a single hs-cTnT strategy only for patients with more than 3 hours since symptom onset, a subgroup analysis was performed for this population. Outcomes were adjudicated on the basis of review of medical records and telephone follow-up. RESULTS: Of 1167 patients enrolled, 125 (10.7%) experienced 30-day MACE and 97 (8.3%) had AMI on the index visit. More than one-third of patients (35.6%) had presenting hs-cTnT concentrations below the limit of detection (5 ng/L), which was 94.4% (95% confidence interval [CI], 88.8-97.7) sensitive for 30-day MACE and 99.0% (95% CI, 94.5-100) sensitive for index AMI. Of 292 patients (25.0%) with hs-cTnT < 5 ng/L and at least 3 hours since symptom onset, only 3 experienced 30-day MACE (sensitivity 97.6%; 95% CI, 93.2-100) and none had AMI within 30 days (sensitivity 100%; 95% CI, 96.3-100). CONCLUSIONS: Among patients with nonischemic electrocardiograms and > 3 hours since symptom onset, low hs-cTnT thresholds on presentation confer a very low risk of 30-day MACE. In the absence of a high-risk clinical presentation, further risk stratification is likely to be low yield.
No takes yet. Share an insight, caveat, or question.
Andruchow et al. (2019) conducted a cohort in Chest pain with nonischemic electrocardiograms (n=1,167). Presenting hs-cTnT < 5 ng/L was evaluated on 30-day MACE (Sensitivity 94.4%, 95% CI 88.8-97.7). Presenting hs-cTnT concentrations below 5 ng/L were 94.4% sensitive (95% CI 88.8-97.7) for 30-day MACE, identifying patients at very low risk when presenting >3 hours after symptom onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: